0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD19

CD19

CD19 Molecule Information

Name:B-lymphocyte antigen CD19
Target Synonym:CD19?T-cell surface antigen Leu-12?B-lymphocyte surface antigen B4?B-lymphocyte antigen CD19?Differentiation antigen CD19?CD_antigen=CD19
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:146
Lastest Research Phase:Approved

CD19 Protein Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
CD9-HP254 Human PE-Labeled Human CD19 (20-291) Protein, Fc Tag
CD9-HP254-structure
CD9-H5258 Human Human CD19 (20-291) Protein, Mouse IgG2a Fc Tag
CD9-H5258-structure
CD9-H5258-sds
CD9-H5258-elisa_1
CD9-HF251 Human FITC-Labeled Human CD19 (20-291) Protein, Fc Tag
CD9-HF251-structure
CD9-HF251-sds
CD9-HF2H2 Human FITC-Labeled Human CD19 (20-291) Protein, His Tag
CD9-HF2H2-structure
CD9-HF2H2-sds
CD9-H5251 Human Human CD19 (20-291) Protein, Fc Tag, low endotoxin (Super affinity)
CD9-H5251-structure
CD9-H5251-sds
CD9-H5251-elisa_1
CD9-H5251-elisa_2
CD9-H5250 Human Human CD19 (20-291) Protein, Llama IgG2b Fc Tag, low endotoxin
CD9-H5250-structure
CD9-H5250-sds
CD9-H5250-elisa_1
CD9-H5250-elisa_2
CD9-H52H2 Human Human CD19 (20-291) Protein, His Tag
CD9-H52H2-structure
CD9-H52H2-sds
CD9-H52H2-elisa_1
CD9-H52H2-elisa_2
CD9-C5251 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque CD19 (20-292) Protein, Fc Tag
CD9-C5251-structure
CD9-C5251-sds
CD9-H5255 Human Human CD19 (20-278) Protein, Fc Tag
CD9-H5255-structure
CD9-H5255-sds
CD9-H8259 Human Biotinylated Human CD19, Fc Tag, ultra sensitivity (primary amine labeling)
CD9-H8259-structure
CD9-H8259-sds
CD9-H8259-elisa_1
CD9-H5259 Human Human CD19 (20-291) Protein, Fc Tag, low endotoxin
CD9-H5259-structure
CD9-H5259-sds
CD9-H5259-elisa_1
CD9-H5259-elisa_2

CD19 Molecule Synonym Name

CD19,B4,CVID3,MGC12802

CD19 Molecule Background

B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I  membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

CD19 References

CD19 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Blinatumomab AMG-103; MEDI-538; MT-103; BiTE-MT-103; bscCD19xCD3 Approved Amgen BLINCYTO fda Acute lymphoblastic leukaemia (ALL) AMGEN 2014-12-03 Acute lymphoblastic leukaemia (ALL) Details
Tisagenlecleucel CART-019; CART-19; CTL-019; LG-740 Approved University of Pennsylvania, Novartis tisagenlecleucel ema Novartis Europharm Limited 2018-08-22 Acute lymphoblastic leukaemia (ALL) Details
Axicabtagene ciloleucel KTE-C19; KTE-X19,KTE C19; KTE X19 Approved Cabaret Biotech, Kite Pharma, Fosun Pharma axicabtagene ciloleucel ema Kite Pharma EU B.V. 2018-08-23 B-cell lymphoma, Diffuse large B cell lymphoma, Follicular lymphoma Details

CD19 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CD19 CAR-T cell therapy (National University of Malaysia) Phase Ⅲ National University of Malaysia Acute lymphoblastic leukaemia (ALL) Details
MC-19PD1 CAR-T cell therapy (Peking University) Phase Ⅱ Peking University B-cell lymphoma Details
ALLO-501 ALLO-501,ALLO 501,ALLO501 Phase Ⅰ Cellectis, Allogene Therapeutics, Servier Non-Hodgkin's lymphoma (NHL) Details
AUT-O3 AUTO-3 Phase Ⅱ University College London, Autolus B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) Phase Ⅰ Institute of Hematology & Blood Diseases Hospital, Zhongyuan Union Cell&Gene Engineering Corp.,Ltd B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
CD19 chimeric antigen receptor T cell therapy (Takara Bio) TBI-1501 Phase Ⅱ TaKaRa Bio, Memorial Sloan-Kettering Cancer Center Non-Hodgkin's lymphoma (NHL) Details
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center) Phase Ⅰ Fred Hutchinson Cancer Research Center Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL), Non-Hodgkin B-cell lymphomas Details
CD19-STAR-T cell therapy (China Immunotech Co., Ltd.) Phase Ⅰ HeBei Yanda hospital, China Immunotech Co., Ltd B-cell lymphoma Details
Anti-CD19 redirected NK cell therapy (National University Health System, Singapore) Phase Ⅰ National University Health System, Singapore Acute lymphoblastic leukaemia (ALL) Details
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) Phase Ⅰ Marino Biotechnology, Chengdu Galaxy Biomed, Peking University B-cell lymphoma Details
NI-204 AP-101; TDI-200; NI-204A Preclinical Neurimmune, ALS Therapy Development Institute Amyotrophic lateral sclerosis (ALS) Details
Anti-CD3-anti-CD19 bispecific monoclonal antibody (Nonindustrial source) Phase Ⅰ Nonindustrial source Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19/CD22 chimeric antigen receptor T cell therapy (Nanjing Legend Biotech) LCAR-L10D Phase Ⅰ Second Affiliated Hospital of Xi'an Jiaotong University, Nanjing Legend Biotech Diffuse large B cell lymphoma Details
SGN-CD19B SGN-CD19B Phase Ⅰ Seattle Genetics Non-Hodgkin's lymphoma (NHL) Details
GC007F (Gracell Biotechnology) GC007F Phase Ⅰ Gracell Biotechnology B-cell lymphoma Details
Taplitumomab paptox Phase Ⅲ University of Minnesota Leukemia Details
aCD19z aCD19z Phase Ⅰ Christie Hospital NHS Foundation Trust, Cellular Therapeutics Non-Hodgkin's lymphoma (NHL) Details
C-CAR011 Phase Ⅱ General Hospital of the People's Liberation Army, Cellular Biomedicine Group, Shanghai saibiman biotechnology Lymphoblastic leukaemia, Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Leukemia, Follicular lymphoma, Non-Hodgkin's lymphoma (NHL) Details
4-1BBz CD19-Her2tG (Seattle Children's Hospital) Phase Ⅰ Seattle Children's Hospital Solid tumours, Cancer Details
A-329 A-329,A 329,A329 Preclinical Generon Corporation B-cell lymphoma Details
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) Phase Ⅰ Memorial Sloan-Kettering Cancer Center Acute lymphoblastic leukaemia (ALL) Details
pCAR-19B Phase Ⅰ Chongqing Precision Biotech Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) yinnuokati-19 Phase Ⅱ Shenzhen Institute for Innovation and Translational Medicine, Dongguan People's Hospital Chronic lymphocytic leukemia (CLL), Lymphoma, Acute lymphoblastic leukaemia (ALL) Details
CD19CAR CD19CAR Phase Ⅰ City of Hope National Medical Center, National Cancer Institute Lymphomatoid granulomatosis, Hairy cell leukemia, Lymphoma Details
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) Phase Ⅱ Chaim Sheba Medical Center at Tel HaShomer Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
GTB-1550 DT-2219ARL; DT-2219; IND-100780; OXS-1550 Phase Ⅱ University of Minnesota, Oxis International, GT Biopharma B-cell lymphoma, Leukemia Details
Senl-1904A Senl-1904A; Senl_1904A Phase Ⅰ Hebei Senlang BIOTECHNOLOGY Co., LTD Lymphoblastic leukaemia Details
Anti-CD22/CD19 monoclonal antibody-toxin conjugate Phase Ⅰ University of Texas Southwestern Medical Center, Galileo Research B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
YTB-323 YTB-323 Phase Ⅰ Novartis Small lymphocytic lymphoma (SLL), Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL) Details
AUTO-1 AUTO1; AUTO-1 Phase Ⅱ University College London, Autolus Burkitt's lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR T-cell therapy (Nanjing CART Medical Technology) Phase Not Specified Nanjing CART Medical Technology B-cell malignancies Details
Anti-CD19 CAR T cell therapy (Shanghai GeneChem) Phase Ⅱ Shanghai GeneChem Leukemia, Systemic lupus erythematosus Details
CD19-CART Phase Ⅱ Shanghai Hrain Biotechnology Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Dual specificity CD19 and CD20 or CD22 CAR-T cell (Chinese PLA General Hospital) Phase Ⅱ General Hospital of the People's Liberation Army B-cell lymphoma, Leukemia Details
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) Phase Ⅱ Wuhan Sian Medical Technology, Wuhan Union Hospital, Jingzhou Central Hospital, Xiangyang Central Hospital, The First People's Hospital of Yuhang District B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Anti CD19 chimeric antigen receptor T cell therapy (Gracell Biotechnology) Phase Ⅰ Gracell Biotechnology B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) Phase Ⅰ City of Hope National Medical Center Non-Hodgkin's lymphoma (NHL) Details
AFM-11 AFM-11 Phase Ⅰ Affimed Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) Phase Ⅰ iCarTAB Biomed Leukemia, Lymphoma Details
B-193 B-193 Preclinical Shanghai Yanyi Biotechnology, Buchang Pharma Cancer Details
BinD-19 (Shenzhen BinDeBio) BinD-19 IND Filing BinDeBio Lymphoblastic leukaemia, B-cell lymphoma Details
CLIC-1901 (Ottawa Hospital Research Institute) CLIC-1901 Phase Ⅱ Ottawa Hospital Research Institute Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) Phase Ⅰ UCLAs Jonsson Comprehensive Cancer Center Chronic lymphocytic leukemia (CLL), B-cell lymphoma Details
Anti-CD19 CAR T-cell therapy (Shanghai Children's Medical Center) Phase Ⅱ Miltenyi Biotec, Shanghai Children's Medical Center Chronic lymphocytic leukemia (CLL), B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-19,4SCAR19,4SCAR 19 Phase Ⅱ Shenzhen Geno-Immune Medical Institute B-cell lymphoma Details
IM19CAR-T Phase Ⅱ Beijing Immunochina Medical Science & Technology Leukemia, Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) Phase Not Specified Leidos Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) PZ-01 Phase Not Specified Pinze Lifetechnology B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
3rd-gen-CD19-CAR 3rd-gen-CD19-CAR Phase Ⅱ bluebird bio, Celgene B-cell lymphoma, Leukemia Details
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) BPX-401,BPX 401,BPX401 Phase Ⅱ Bellicum, Ospedale Pediatrico Bambino Gesu Leukemia, Lymphoma, Acute lymphoblastic leukaemia (ALL) Details
CD19-CAR-T cell therapy (China Immunotech Co., Ltd.) Phase Ⅰ HeBei Yanda hospital, China Immunotech Co., Ltd B-cell lymphoma Details
CART-19 cells (Henan Hualong Biotechnology) Phase Ⅱ Henan Hualong Biotechnology Lymphoblastic leukaemia Details
CD19 CAR-T cell (Pregene) Phase Ⅱ Pregene B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
FH-2494 FH-2494 Phase Ⅱ Fred Hutchinson Cancer Research Center, National Cancer Institute Leukemia, Lymphoma Details
MDX 1342 MDX-1342 Phase Ⅰ Medarex Chronic lymphocytic leukemia (CLL), Rheumatoid arthritis (RA) Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) Phase Ⅰ Seattle Children's Hospital Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR T-cell therapy (University College London) 4G7-CARD Phase Ⅰ University College London Lymphoma Details
Anti-CD19 CAR T-cell therapy (Nanjing Medical University) XLCART-001 Phase Ⅱ Nanjing Medical University B-cell lymphoma Details
A-319 A-319,A319 Phase Ⅰ Generon Corporation B-cell lymphoma, Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL) Details
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) Phase Ⅱ Soochow University Acute lymphoblastic leukaemia (ALL) Details
Oncolysin B Phase Ⅲ ImmunoGen Leukemia, Lymphoma, Non-Hodgkin's lymphoma (NHL) Details
CD19.CAR T Cells (University Hospital Heidelberg) Phase Ⅱ University of Heidelberg Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), Follicular lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) Phase Ⅰ Nagoya University, Shinshu University, Japan Tissue Engineering, Fujifilm group Acute lymphoblastic leukaemia (ALL) Details
BZ019 BZ-019 Phase Ⅰ Shanghai Cell Therapy Research Institute Diffuse large B cell lymphoma, Primary mediastinal B cell lymphoma, Follicular lymphoma Details
MOR-208 MOR-208; MOR-00208; XENP-5574; XmAb-5574 Phase Ⅲ Xencor, MorphoSys Chronic lymphocytic leukemia (CLL), Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) Phase Ⅰ Immune Cell, Weifang People's Hospital Lymphoblastic leukaemia, B-cell lymphoma Details
K193 bispecific antibody K-193 Phase Ⅰ Beijing Luzhu Biotechnology B-cell lymphoma Details
Anti-CD19 CAR-T cell therapy (Shanghai Bioray Laboratory) Phase Ⅱ Shanghai Bioray Laboratory Inc Leukemia Details
TAC01-CD19 TAC01-CD19 Phase Ⅱ Triumvira Immunologics B-cell lymphoma Details
CD19 CAR-T (HuaDao CAR-Tcell) IND Filing HuaDao CAR-Tcell Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
JCAR-015 JCAR-15; JCAR-015; 19-28z CAR T cells; 19-28z+ T cells; 19-28z-T-Cells Phase Ⅱ Fred Hutchinson Cancer Research Center, Juno Therapeutics, Seattle Children's Research Institute, Memorial Sloan-Kettering Cancer Center, Celgene, TaKaRa Bio Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) Phase Ⅰ Shanghai Jiaotong University Acute lymphoblastic leukaemia (ALL) Details
Inebilizumab MEDI-551; 16C4-aFuc; 74T7185BMM (UNII code) Phase Ⅲ MedImmune, Hansoh Pharma Diffuse large B cell lymphoma, Multiple sclerosis (MS), Systemic sclerosis, Neuromyelitis optica (NMO) Details
HuCART19 Phase Ⅰ Kite Pharma, National Cancer Institute B-cell malignancies Details
Denintuzumab mafodotin SGN-19A; SGN-CD19A Phase Ⅱ Seattle Genetics Diffuse large B cell lymphoma, Follicular lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
CTL-119 CTL-119 Phase Ⅰ University of Pennsylvania, Novartis Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
ICT19G1 ICT-19G1 Phase Ⅰ Innovative Cellular Therapeutics Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) Phase Ⅱ Hrain Biotechnology, Fudan University Zhongshan Hospital Diffuse large B cell lymphoma, Follicular lymphoma Details
4G7SDIE Phase Not Specified Synimmune, The University of Tubingen Acute lymphoblastic leukaemia (ALL) Details
Coltuximab ravtansine SAR-3419; huB4-DM4 Phase Ⅱ ImmunoGen, Sanofi Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
AMG-562 AMG-562 Phase Ⅰ Amgen Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Follicular lymphoma Details
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) Phase Ⅱ Southwest Hospital Chongqing Diffuse large B cell lymphoma Details
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) Phase Ⅰ Tianjin Mycure Medical Technology Acute lymphoblastic leukaemia (ALL) Details
Chimeric antigen receptor T cell therapeutics (Shanghai Unicar-Therapy Bio-medicine) Phase Ⅱ Shanghai Unicar-Therapy Bio-medicine Technology Lymphoblastic leukaemia, Multiple myeloma (MM), Acute lymphoblastic leukaemia (ALL), Lymphoma, Non-Hodgkin's lymphoma (NHL), Pancreatic cancer Details
19-28z+ 19-28z+ Phase Ⅱ Memorial Sloan-Kettering Cancer Center, Dana-Farber Cancer Institute Leukemia Details
UCART-19 UCART-19; S-68587 Phase Ⅰ Cellectis, Pfizer, Servier Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL) Details
CD19-CAR CD19-CAR Phase Ⅰ M.D. Anderson Cancer Center, Ziopharm Oncology, Intrexon Corporation Leukemia, Lymphoma Details
CD19.CAR-VST CD19.CAR-VST Phase Ⅰ Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) Phase Ⅰ Stanford University B-cell lymphoma Details
TI-1007 (Timmune Biotech) TI-1007,TI 1007,TI1007 Phase Ⅱ Timmune Biotech Non-Hodgkin's lymphoma (NHL) Details
CD19-CART (PD-1 knockdown, Unicar-Therapy Bio-medicine Technology) IND Filing Unicar-Therapy Bio-medicine Technology Lymphoma Details
Virus-specific-CD19.CAR Phase Ⅰ Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 CAR-T cell therapy (Juventas) CNCT19 IND Filing Juventas Cancer Details
JWCAR-029 JWCAR-029,JWCAR029; JWCAR 029 Phase Ⅱ Shanghai Mingju Biological Technology Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) Phase Ⅰ Juno Therapeutics Chronic lymphocytic leukemia (CLL) Details
JCAR-014 JCAR-014 Phase Ⅱ Fred Hutchinson Cancer Research Center, Juno Therapeutics, Seattle Children's Research Institute, Memorial Sloan-Kettering Cancer Center, Celgene Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
Anti-CD19 CAR-T cell therapy (Bioceltech) Phase Not Specified Bioceltech Therapeutics Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR-T cell therapy (Uppsala University) Phase Ⅱ Uppsala University B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) Phase Ⅰ Kunming Medical University B-cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) Phase Ⅱ Southwest Hospital Chongqing Diffuse large B cell lymphoma Details
ET190L1-ARTEMIS T cells (Eureka Therapeutics) ET-190; ET190; ET190L1; ET190L1-ARTEMI Phase Ⅰ Eureka therapeutics, Duke University Chronic lymphocytic leukemia (CLL), B-cell lymphoma, Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) SENL-B19,SENL-B-19 Phase Ⅱ Hebei Senlang BIOTECHNOLOGY Co., LTD B-cell lymphoma, hematological malignancies, Acute lymphoblastic leukaemia (ALL) Details
Monoclonal antibody B43 Genistein-conjugate Phase Ⅰ University of Minnesota, Bristol-Myers Squibb Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) Phase Ⅰ Medical College of Wisconsin B-cell malignancies, Cancer Details
DI-B4 DI-B4 Phase Ⅰ Cancer Research UK, Merck Serono B-cell lymphoma, Chronic lymphocytic leukemia (CLL) Details
Anti-CD19 chimeric antigen receptor T cell therapy (Yake) YK-C19 Phase Not Specified Yake Biotechnology Lymphoblastic leukaemia, B-cell lymphoma Details
Lisocabtagene maraleucel (Celgene/Juno Therapeutics) JCAR-017; Liso-Cel Phase Ⅲ Fred Hutchinson Cancer Research Center, Juno Therapeutics, Seattle Children's Research Institute, Memorial Sloan-Kettering Cancer Center, Celgene Non-Hodgkin's lymphoma (NHL) Details
anti-CD19 CAR T-cell (Henan Cancer Hospital) Phase Ⅱ Henan Cancer Hospital, Pregene Acute lymphoblastic leukaemia (ALL) Details
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) Phase Ⅰ Henan Cancer Hospital B-cell lymphoma Details
Anti-CD19 CAR T-cell therapy (Fujian Medical University) Phase Ⅲ Fujian Medical University Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL) Details
Modified anti-CD19 T-cell therapy (Fred Hutchinson Cancer Research Center) Phase Ⅰ Fred Hutchinson Cancer Research Center B-cell malignancies Details
CD19/CD3 Preclinical YZY Bio Lymphoma Details
Anti-CD19 CAR-T cell therapy (PersonGen Biomedicine) PCAR-019,PCAR 019,PCAR019 Phase Ⅱ PersonGen Biomedicine Leukemia, Lymphoma Details
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) Phase Ⅱ Xuanwu Hospital of Capital Medical University Acute lymphoblastic leukaemia (ALL) Details
ET-019002 ET-019002 Phase Ⅰ Eureka therapeutics Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
EBV-CTL (Atara/MSKCC) EBV-CTL-Atara-MSKCC Preclinical Memorial Sloan-Kettering Cancer Center, Atara Biotherapeutics EBV-associated post-transplant lymphoproliferative disease (PTLD) Details
Chimeric antigen receptor-modified autologous T cell injection targeting CD19 (Bio-gene) BG-T19 Phase Ⅰ Guangzhou Bio-gene Technology Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
Obexelimab XmAb-5871; AMG-729 Phase Ⅱ Xencor Autoimmune diseases, Systemic lupus erythematosus, Rheumatoid arthritis (RA) Details
因诺卡替-19细胞 IND Filing Shenzhen Innovation Immunotechnology Lymphoblastic leukaemia Details
CD19-specific T-cell therapy (B cell malignancies), Christie NHS Foundation Trust Phase Ⅰ Christie Hospital NHS Foundation Trust, Cancer Research UK, University of Manchester Non-Hodgkin B-cell lymphomas Details
Duvortuxizumab JNJ-64052781; MGD-011 Phase Ⅰ MacroGenics, Janssen Mantle cell lymphoma (MCL), Diffuse large B cell lymphoma, Chronic lymphocytic leukemia (CLL), hematological malignancies, Follicular lymphoma, Malignancies Details
Chimeric antigen receptor T-cell therapy (Hebei Senlang Biotechnology) Senl_B19 Phase Ⅱ Hebei Senlang BIOTECHNOLOGY Co., LTD hematological malignancies Details
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) Phase Ⅰ Timmune Biotech Non-Hodgkin's lymphoma (NHL) Details
Loncastuximab tesirine ADCT-402 Phase Ⅱ ADC Therapeutics Diffuse large B cell lymphoma, Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
AFM-24 AFM-12; AFM-18; AFM-20; AFM-21; AFM-22; AFM-24; AFM-24+; AFM-26; AFM-26+ Preclinical Affimed, Amphivena Therapeutics Colorectal cancer, Lung cancer, Acute myeloid Leukemia (AML), Head and neck cancer, Cancer Details
Anti-CD19 chimeric antigen receptor T cell therapy (Wuhan Sian Medical Technology) Phase Ⅰ Wuhan Sian Medical Technology Acute lymphoblastic leukaemia (ALL) Details
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) Phase Ⅱ University of Alberta Acute lymphoblastic leukaemia (ALL), Non-Hodgkin B-cell lymphomas Details
U-CART (Shanghai Bioray Laboratory Inc) Phase Ⅱ Shanghai Bioray Laboratory Inc hematological malignancies, Acute lymphoblastic leukaemia (ALL) Details
PBCAR-0191 PBCAR-0191 Phase Ⅱ Baxalta, Precision Biologics Lymphoblastic leukaemia, Non-Hodgkin's lymphoma (NHL) Details
PCAR-119 (PersonGen Biomedicine) PCAR-119,PCAR 119,PCAR119 Phase Ⅱ PersonGen Biomedicine Leukemia, Lymphoma Details
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) Phase Ⅱ National Institute of Allergy and Infectious Diseases, University of Pittsburgh Primary humoral immunodeficiency Details
CAR-T 19 (University of Pennsylvania) Phase Ⅱ University of Pennsylvania Leukemia, Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) CARCIK-CD19; CIK-CAR.CD19 Phase Ⅱ Fondazione Matilde Tettamanti Menotti De Marchi Onlus Acute lymphoblastic leukaemia (ALL) Details
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) Phase Not Specified Wuhan Bio-Raid Biotechnology B-cell lymphoma, Multiple myeloma (MM) Details
CAR-CD19 T cell therapy CT-032,CT032; CT 032 Phase Ⅰ CARsgen Therapeutics B-cell lymphoma, Leukemia Details
Anti-CD19 CAR-T cell therapy (Sinobioway) Phase Ⅱ Sinobioway Biomedicine Diffuse large B cell lymphoma, Lymphoma Details
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) Phase Ⅰ Guangzhou Institutes of Biomedicine and Health (GIBH) Acute lymphoblastic leukaemia (ALL) Details
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) IND Filing Unicar-Therapy Bio-medicine Technology Acute lymphoblastic leukaemia (ALL), Central nervous system leukemia Details
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) Phase Ⅰ General Hospital of the People's Liberation Army Leukemia, Lymphoma Details
Senl-1904B Senl-1904B; Senl_1904B Phase Ⅰ Hebei Senlang BIOTECHNOLOGY Co., LTD Lymphoblastic leukaemia Details
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) Phase Ⅰ Dana-Farber Cancer Institute, Memorial Sloan-Kettering Cancer Center, Boston Children's Hospital Leukemia Details
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) Phase Not Specified Hebei Senlang BIOTECHNOLOGY Co., LTD Leukemia Details
H-31970-SAGAN H-31970-SAGAN Phase Ⅰ Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital System Chronic lymphocytic leukemia (CLL), Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) Phase Ⅱ Innovative Cellular Therapeutics, Zhejiang University, Kunming Medical University Lymphoblastic leukaemia, Diffuse large B cell lymphoma, B-cell lymphoma, Leukemia, Follicular lymphoma, Non-Hodgkin's lymphoma (NHL) Details
TG-1801 TG-1801; NI-1701 Phase Ⅰ NovImmune, TG Therapeutics B-cell lymphoma Details
PCAR-019 (Anke Biotechnology) Phase Ⅱ Anke Biotechnology Acute lymphoblastic leukaemia (ALL), Non-Hodgkin's lymphoma (NHL) Details

This web search service is supported by Google Inc.

totop